The Food and Drug Administration (FDA) gave clearance for a Phase 1 trial for the research product AGT103-T starting this September in Washington and Baltimore. AGT103-T is developed from blood cells using an 11-day process that increased T-cells, which fight HIV, but uses a lentiviral vector-based gene therapy. Lentiviral vectors in gene therapy is a method by which genes can be inserted, modified, or deleted in organisms using lentivirus. Lentivirus are a family of viruses that infect by inserting DNA into their host cells’ genome. In preclinical studies, the company said AGT103-T demonstrated the ability to clear itself of HIV when challenged with the virus and HIV-infected cells.